High Sustained Virologic Response Rates in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection Receiving ABT-450/r/Ombitasvir plus Dasabuvir Plus Ribavirin

被引：0
|
作者：
Mantry, Parvez S. [1 ]
Kwo, Paul Y. [2 ]
Coakley, Eoin [3 ]
Te, Helen S. [4 ]
Vargas, Hugo E. [5 ]
Brown, Robert S. [6 ]
Gordon, Fredric D. [7 ]
Levitsky, Josh [8 ]
Terrault, Norah [9 ]
Burton, James R. [10 ]
Xie, Wangang [3 ]
Setze, Carolyn [3 ]
Badri, Prajakta [3 ]
Vilchez, Regis A. [3 ]
Forns, Xavier [11 ,12 ]
机构：
[1] Liver Inst Methodist Dallas, Dallas, TX USA
[2] Indiana Univ, Indianapolis, IN 46204 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Univ Chicago Med, Chicago, IL USA
[5] Mayo Clin, Mayo Clinic, AZ 5 USA
[6] Columbia Univ, Ctr Liver Dis & Transplantat, Med Ctr, New York, NY USA
[7] Lahey Hosp & Med Ctr, Burlington, MA USA
[8] Northwestern Univ, Comprehens Transplant Ctr, Chicago, IL 60611 USA
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
[10] Univ Colorado, Denver, CO 80202 USA
[11] IDIBAPS, Hosp Clin, Liver Unit, Barcelona, Spain
[12] CIBEREHD, Barcelona, Spain
来源：
HEPATOLOGY | 2014年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
198
引用
收藏
页码：298A / 299A
页数：2
相关论文
共 50 条
  • [21] Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study
    Poordad, Fred
    Agarwal, Kosh
    Younes, Ziad
    Cohen, Daniel
    Xie, Wangang
    Podsadecki, Thomas
    CLINICAL INFECTIOUS DISEASES, 2015, 60 (04) : 608 - 610
  • [22] SVR12 Rate of 95.7% in 209 HCV Genotype 1-Infected Null Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
    Jacobson, Ira M.
    DuFour, Jean-Francois J.
    Enejosa, Jeffrey
    de Knegt, Robert J.
    Ferenci, Peter
    Reynaert, Hendrik
    Di Bisceglie, Adrian M.
    Larsen, Lois
    Baykal, Tolga
    Rodrigues-, Lino, Jr.
    Podsadecki, Thomas
    Jensen, Donald M.
    Poordad, Fred
    HEPATOLOGY, 2014, 60 : 1133A - 1133A
  • [23] SVR12 of 99% Achieved With a Ribavirin-Free Regimen of ABT-450/r/Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients
    Maieron, Andreas
    Puoti, Massimo
    Enejosa, Jeffrey
    Ben-Ari, Ziv
    Norkrans, Gunnar
    Romero-Gomez, Manuel
    Xie, Wangang
    Cohen, Daniel
    Podsadecki, Thomas
    Andreone, Pietro
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S131 - S131
  • [24] Sustained Virologic Response 12 Weeks Post-Treatment With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With Ribavirin (SAPPHIRE I and II) is Independent of Patient Subgroups
    Brunetto, Maurizia Rossana
    Makara, Mihaly
    Hinrichsen, Holger
    Hanson, John
    Bennett, Michael
    Lawitz, Eric
    Xiong, Junyuan
    Coakley, Eoin
    Baykal, Tolga
    Neff, Guy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S133 - S133
  • [25] SVR12 of 99% achieved with a ribavirin-free regimen ABT-450/R/ombitasvir and dasabuvir in HCV genotype 1b-infected patients
    Maieron, A.
    Puoti, M.
    Enejosa, J. V.
    Andreone, P.
    Ari, Z. B.
    Norkrans, G.
    Romero-Gomez, M.
    Xie, W.
    Cohen, D. E.
    Podsadecki, T.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 156 - 156
  • [26] SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
    Colombo, Massimo
    Weiland, Ola
    Cohen, Daniel E.
    DuFour, Jean-Francois J.
    Reynaert, Hendrik
    Diago, Moises
    Villa, Erica
    Streinu-Cercel, Adrian
    Xie, Wangang
    Baykal, Tolga
    Enejosa, Jeffrey
    Coakley, Eoin
    Trinh, Roger
    Podsadecki, Thomas
    HEPATOLOGY, 2014, 60 : 1131A - 1131A
  • [27] Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks
    Feld, Jordan J.
    Moreno, Christophe
    Trinh, Roger
    Tam, Edward
    Bourgeois, Stefan
    Horsmans, Yves
    Elkhashab, Magdy
    Bernstein, David E.
    Younes, Ziad
    Reindollar, Robert W.
    Larsen, Lois
    Fu, Bo
    Howieson, Kevin
    Polepally, Akshanth R.
    Pangerl, Andreas
    Shulman, Nancy S.
    Poordad, Fred
    JOURNAL OF HEPATOLOGY, 2016, 64 (02) : 301 - 307
  • [28] TURQUOISE-II: Regimens of ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients with Cirrhosis, Regardless of Baseline Characteristics
    Fried, Michael W.
    Forns, Xavier
    Reau, Nancy
    Wedemeyer, Heiner
    Shiffman, Mitchell L.
    Castro, Angeles
    Mutimer, David J.
    Lee, Samuel S.
    Trinh, Roger
    Lovell, Sandra S.
    Canizaro, Leticia
    Pedrosa, Marcos
    Berg, Thomas
    HEPATOLOGY, 2014, 60 : 238A - 238A
  • [29] RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267+ABT-333+RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION
    Kwo, P.
    Mantry, P.
    Coakley, E.
    Te, H.
    Vargas, H.
    Brown, R., Jr.
    Gordon, F.
    Levitsky, J.
    Terrault, N.
    Burton, J., Jr.
    Xie, W.
    Setze, C.
    Badri, P.
    Vilchez, R. A.
    Forns, X.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S47 - S48
  • [30] PEARL-IV Trial: Subgroup Analysis of Genotype 1a-Infected Patients Treated With ABT-450/r/Ombitasvir With Dasabuvir With or Without Ribavirin
    Bernstein, David Eric
    Luo, Yan
    Lalezari, Jacob P.
    Wyles, David L.
    King, William
    Tsai, Naoky
    Davis, Mitchell N.
    Sepe, Thomas E.
    Fessel, Jeffrey
    King, Martin
    Podsadecki, Thomas
    Cooper, Curtis
    HEPATOLOGY, 2014, 60 : 1132A - 1133A
12345